



Leading the way in cell & gene therapy as a global CDMO

Dr. Frank Mathias
Chief Executive Officer

Legal disclaimer


This presentation does not constitute an offer to sell or a solicitation of offers to buy Ordinary Shares (the “Securities”). Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, the contents of this presentation have not been formally verified by Oxford Biomedica plc (“OXB” or the “Company”) or any other person. Accordingly, no representation or warranty, expressed or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this presentation, and no reliance should be placed on such information or opinions. Further, the information in this presentation is not complete and may be changed. Neither the Company nor any of its respective members, directors, officers or employees nor any other person accepts any liability whatsoever for any loss howsoever arising from any use of such information or opinions or otherwise arising in connection with this presentation.

This presentation may contain forward-looking statements that reflect the Company's current expectations regarding future events, its liquidity and results of operations and its future working capital requirements. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and may depend on a number of factors.



OXB provides a critical capability for cell & gene therapies

OXB's viral vector expertise is a vital link between scientific breakthroughs and patients




OXB provides end-to-end viral vector manufacturing expertise to pharma & biotech clients

CGT outsourcing is entering a sustained growth phase

Consistent pipeline expansion across all development stages and momentum in approvals

The CGT market is becoming increasingly outsourceable as more programmes mature and developers require specialist manufacturing partners

Gene therapy pipeline annual comparison
Number of CGT programmes⁽¹⁾



\$10bn

CGT CDMO market by 2031


\$11.9bn

in CGT M&A deals in last year

38

approved CGT products globally

Outsourced potential market growth:



4 Sources: (1) Company estimates and third-party research





Cell and gene therapy is shifting the paradigm of medicine



Vision

To transform lives through cell and gene therapy



Mission

To enable our clients to deliver life-changing therapies to patients



Strategy

To lead the cell and gene therapy CDMO field as a trusted partner with unmatched quality and innovation

30+

years of experience

1,000+

batches

85+

total client programmes (cumulative)

100+

audits

The making of a world-leading viral vector CDMO


Delivering on our pure-play CDMO strategy

OXB has completed a strategic transformation and is now scaling as a global CDMO, with revenue increasing from £89.5m in FY23 to £170.9m (CC¹) in FY25. FY26 revenues are expected to be between £220-240m.

Transformation period revenue growth: FY23: £89.5m

FY24: £128.8m

FY25: £170.9m (CC¹)



OXB's end-to-end global capabilities across key biotech hubs

Global multi-vector network designed to support clients from development to commercial supply



Management with strong CDMO and value creation expertise

Dr. Frank Mathias

Chief Executive Officer
(experience: >35 yrs)



Dr. Lucy Crabtree

Chief Financial Officer
(experience: >20 yrs)



Dr. Kyriacos Mitrophanous

Chief Innovation Officer
(experience: >25 yrs)



Dr. Sébastien Ribault

Chief Business Officer
(experience: >25 yrs)



Dr. Melanie Kearney

Head of Global Quality
(experience: >30 yrs)



Lisa Doman

Chief People Officer
(experience: >15 yrs)



Natalie Walter

Chief Legal Officer
(experience: >25 yrs)



Dr. Sabine Sydow

Chief of Staff
(experience: >25 yrs)



>200

years of
combined
experience

Positioned to win and drive sustainable outperformance

A differentiated platform built to outperform across infrastructure, innovation and commercial execution



01

Global, Scalable Infrastructure

Our network delivers at every stage

02

Process Development Excellence

We solve problems others can't

03

Innovation-Led Platform

We stay ahead of client needs

04

Commercial Momentum

Our pipeline and order book demonstrate it

Let's deliver life-changing therapies together

A global quality and innovation-led
CDMO in cell and gene therapy

[OXB.com](https://www.oxb.com)

